Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)

NCT04462406 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04462406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04462406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 9, 2021
Completion date
September 30, 2030
Enrollment
150 (estimated)
Sites
482

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, melanoma of unknown primary, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, unresectable acral lentiginous melanoma, unresectable melanoma, unresectable mucosal melanoma